New asthma drug formulation put to the test in healthy adults

NCT ID NCT07231861

Not yet recruiting Knowledge-focused Sponsor: AJU Pharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two oral formulations of pranlukast, a drug used for asthma and allergic rhinitis, to see if they are equivalent. Sixty healthy adults will receive a single dose of each version in random order under fasting conditions. The main goal is to measure drug levels in the blood, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pranlukast hydrate
What this could lead to: If successful, this study could confirm that the new formulation of pranlukast works the same as the existing one, potentially offering a generic alternative for asthma and allergy treatment.
What could go wrong: This is an early Phase 1 trial in healthy volunteers, not patients. It only checks drug levels in the blood, not whether the drug actually helps symptoms. The results may not predict real-world effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma perennial allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIAL ASTHMA PERENNIAL ALLERGIC RHINITIS

Contacts and locations

Locations

H Plus Yangji Hospital

Seoul, 08779, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.